Powered by the world’s largest recontactable platform of genetic and phenotypic data, and an experienced team with the ability to leverage it, we focus on developing therapeutic antibodies with high-value targets that are central mediators of biological processes.
23andMe Therapeutics has advanced two immuno-oncology programs into the clinic. 23ME-00610 is a first-in-class clinical investigational therapeutic antibody generated in-house and designed to restore the ability of the body’s immune cells to kill cancer cells by blocking the immunosuppressive checkpoint receptor CD200R1. It is currently enrolling the Phase 2a portion of a Phase 1/2a study.
23ME-01473 is an NK cell-activating investigational therapeutic antibody targeting the NKG2D ligand ULBP6.
"We look forward to leveraging our unique database, along with advancements in AI and ML, to further advance therapeutic programs at 23andMe, both independently and with collaborators."
Anne Wojcicki
CEO & Co-Founder
We seek development collaborators to help us realize the full clinical and commercial potential of our immuno-oncology programs. We also seek innovative, future-forward research teams to embark with us on the discovery and early development of novel, genetically validated targets. Lastly, we invite inquiries from teams interested in leveraging our database for in silico discovery partnerships.